Jean‐Louis Chiasson

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis et al. · The Lancet · 2002 · 2.5K citations

Metabolic Syndrome, Disease Management, Diabetes Management +9

Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance

Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis et al. · JAMA · 2003 · 1.6K citations

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein

Thomas M.S. Wolever, Alison L. Gibbs, Christine C. Mehling et al. · American Journal of Clinical Nutrition · 2008 · 332 citations · Full text

Metabolic Syndrome, Nutrition, Diabetes Management +9